J2WA34 Stock Overview
John Wiley & Sons, Inc. operates as a research and education company worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 1/6 |
Financial Health | 2/6 |
Dividends | 5/6 |
John Wiley & Sons, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$53.10 |
52 Week High | US$53.10 |
52 Week Low | US$53.10 |
Beta | 0.90 |
1 Month Change | 0% |
3 Month Change | 1.10% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 7.45% |
Recent News & Updates
Recent updates
Shareholder Returns
J2WA34 | BR Media | BR Market | |
---|---|---|---|
7D | 0% | 0.8% | -0.6% |
1Y | n/a | 6.7% | 9.7% |
Return vs Industry: Insufficient data to determine how J2WA34 performed against the BR Media industry.
Return vs Market: Insufficient data to determine how J2WA34 performed against the BR Market.
Price Volatility
J2WA34 volatility | |
---|---|
J2WA34 Average Weekly Movement | n/a |
Media Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in BR Market | 9.0% |
10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: J2WA34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine J2WA34's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1807 | 9,500 | Brian Napack | www.wiley.com |
John Wiley & Sons, Inc. operates as a research and education company worldwide. The company operates through three segments: Research Publishing & Platforms, Academic & Professional Learning, and Education Services. The Research Publishing & Platforms segment offers scientific, technical, medical, and scholarly journals, as well as related content and services to learned societies, individual researchers, other professionals, and academic, corporate, and government libraries.
John Wiley & Sons, Inc. Fundamentals Summary
J2WA34 fundamental statistics | |
---|---|
Market cap | R$11.13b |
Earnings (TTM) | R$606.04m |
Revenue (TTM) | R$10.82b |
18.4x
P/E Ratio1.0x
P/S RatioIs J2WA34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
J2WA34 income statement (TTM) | |
---|---|
Revenue | US$2.08b |
Cost of Revenue | US$645.83m |
Gross Profit | US$1.44b |
Other Expenses | US$1.32b |
Earnings | US$116.64m |
Last Reported Earnings
Jul 31, 2022
Next Earnings Date
Dec 07, 2022
Earnings per share (EPS) | 2.09 |
Gross Margin | 68.98% |
Net Profit Margin | 5.60% |
Debt/Equity Ratio | 86.9% |
How did J2WA34 perform over the long term?
See historical performance and comparison